Vertex Pharmaceuticals Stock Price Target and Analyst Ratings (NASDAQ:VRTX)

Analyst Price Target for VRTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$292.68

▲ +37.04% Upside Potential

This price target is based on 27 analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $292.68, with a high forecast of $347.00 and a low forecast of $250.00. The average price target represents a 37.04% upside from the last price of $213.58.

Buy

The current consensus among 27 polled investment analysts is to buy stock in Vertex Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

1 strong buy ratings
13 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

9/15/2019

1 strong buy ratings
17 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

12/14/2019

1 strong buy ratings
21 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

3/13/2020

1 strong buy ratings
22 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

6/11/2020

1 strong buy ratings
22 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

9/9/2020

1 strong buy ratings
24 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

12/8/2020

1 strong buy ratings
22 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

2/6/2021

1 strong buy ratings
22 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

3/8/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
3/1/2021	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$220.00 ➝ $252.00	Low	i Rating by Brian Skorney at Robert W. Baird
2/23/2021	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$220.00 ➝ $252.00	Medium	i
2/2/2021	BMO Capital Markets	Lower Price Target	Outperform	$302.00 ➝ $284.00	Low	i
2/2/2021	Credit Suisse Group	Lower Price Target	Outperform	$285.00 ➝ $280.00	Low	i
2/2/2021	SVB Leerink	Lower Price Target	Market Perform	$257.00 ➝ $250.00	Low	i
2/2/2021	Piper Sandler	Boost Price Target	Overweight	$307.00 ➝ $347.00	Low	i
2/2/2021	HC Wainwright	Lower Price Target	Buy	$315.00 ➝ $275.00	Low	i
1/19/2021	Morgan Stanley	Boost Price Target	Equal Weight	$249.00 ➝ $251.00	Low	i
12/30/2020	Daiwa Capital Markets	Initiated Coverage	Outperform	$250.00	N/A	i
12/11/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low	i
11/30/2020	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$247.00 ➝ $267.00	Low	i
11/20/2020	Sanford C. Bernstein	Initiated Coverage	Outperform	$275.00	Low	i
11/1/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low	i
10/30/2020	Piper Sandler	Lower Price Target	Overweight	$327.00 ➝ $307.00	Low	i
10/30/2020	Credit Suisse Group	Lower Price Target	Outperform	$292.00 ➝ $285.00	Low	i
10/30/2020	SVB Leerink	Lower Price Target	Market Perform	$267.00 ➝ $257.00	High	i
10/28/2020	UBS Group	Initiated Coverage	Buy	$287.00	Low	i
10/26/2020	Needham & Company LLC	Reiterated Rating	Hold		Medium	i
10/19/2020	Morgan Stanley	Lower Price Target	Equal Weight	$281.00 ➝ $249.00	Medium	i
10/15/2020	Truist	Lower Price Target		$330.00 ➝ $305.00	High	i
10/15/2020	SVB Leerink	Lower Price Target	Market Perform	$283.00 ➝ $267.00	High	i
10/13/2020	Morgan Stanley	Lower Price Target	Equal Weight	$300.00 ➝ $281.00	Low	i
9/18/2020	Maxim Group	Reiterated Rating	Hold		High	i
8/24/2020	SVB Leerink	Boost Price Target	Neutral ➝ Market Perform	$274.00 ➝ $283.00	Medium	i
7/31/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$293.00 ➝ $305.00	High	i Rating by Alethia Young at Cantor Fitzgerald
7/31/2020	SVB Leerink	Boost Price Target	Market Perform	$263.00 ➝ $274.00	High	i
7/31/2020	HC Wainwright	Reiterated Rating	Buy	$295.00 ➝ $315.00	High	i
7/31/2020	Piper Sandler	Boost Price Target	Overweight	$302.00 ➝ $327.00	High	i Rating by Edward Tenthoff at Piper Sandler
7/20/2020	Credit Suisse Group	Boost Price Target	Outperform	$298.00 ➝ $328.00	High	i
7/16/2020	Cowen	Boost Price Target	Outperform	$265.00 ➝ $300.00	Low	i
7/14/2020	Jefferies Financial Group	Boost Price Target	Buy	$295.00 ➝ $340.00	High	i
7/8/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$277.00 ➝ $300.00	Medium	i
7/2/2020	The Goldman Sachs Group	Boost Price Target	Positive ➝ Conviction-Buy	$290.00 ➝ $330.00	Low	i
6/24/2020	SunTrust Banks	Boost Price Target	Buy	$285.00 ➝ $330.00	High	i
6/12/2020	Citigroup	Boost Price Target	Top Pick ➝ Buy	$305.00 ➝ $325.00	Low	i
5/15/2020	Argus	Boost Price Target	Buy	$270.00 ➝ $320.00	High	i
5/1/2020	Citigroup	Boost Price Target	Buy	$265.00 ➝ $305.00	Medium	i
4/30/2020	Credit Suisse Group	Reiterated Rating	Buy	$298.00	Medium	i Rating by Evan Seigerman at Credit Suisse Group AG
4/30/2020	Cfra	Boost Price Target	Buy	$286.00 ➝ $297.00	Low	i
4/30/2020	Guggenheim	Boost Price Target	Buy	$266.00 ➝ $290.00	High	i Rating by Whitney Ijem at Guggenheim
4/30/2020	BMO Capital Markets	Boost Price Target	Outperform	$279.00 ➝ $283.00	High	i
4/30/2020	Stifel Nicolaus	Boost Price Target	Buy	$275.00 ➝ $285.00	High	i
4/30/2020	Oppenheimer	Boost Price Target	Outperform	$265.00 ➝ $305.00	High	i
4/30/2020	Morgan Stanley	Boost Price Target	Overweight	$258.00 ➝ $277.00	High	i
4/30/2020	SVB Leerink	Boost Price Target	Market Perform	$224.00 ➝ $263.00	High	i
4/30/2020	JMP Securities	Boost Price Target	Market Outperform	$255.00 ➝ $285.00	High	i
4/30/2020	HC Wainwright	Boost Price Target	Buy	$270.00 ➝ $295.00	High	i
4/28/2020	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$250.00 ➝ $260.00	High	i
4/27/2020	Piper Sandler	Reiterated Rating	Buy	$300.00	High	i Rating by Edward Tenthoff at Piper Sandler
4/15/2020	Morgan Stanley	Boost Price Target	Overweight	$251.00 ➝ $258.00	Medium	i
3/27/2020	Piper Sandler	Reiterated Rating	Buy	$300.00	High	i Rating by Edward Tenthoff at Piper Sandler
3/12/2020	Wolfe Research	Initiated Coverage	Outperform	$282.00	High	i
3/11/2020	Cantor Fitzgerald	Reiterated Rating	Overweight	$262.00 ➝ $275.00	Medium	i
3/4/2020	Barclays	Initiated Coverage	Overweight	$271.00	High	i
3/3/2020	Cowen	Reiterated Rating	Buy	$260.00	Medium	i Rating by Phil Nadeau at Cowen Inc
3/2/2020	Argus	Boost Price Target	Positive ➝ Buy	$248.00 ➝ $270.00	High	i
2/2/2020	Evercore ISI	Reiterated Rating	Hold	$270.00	Medium	i
1/31/2020	Piper Sandler	Boost Price Target		$284.00 ➝ $300.00	Medium	i
1/31/2020	Bank of America	Reiterated Rating	Buy	$250.00 ➝ $295.00	High	i
1/31/2020	Needham & Company LLC	Reiterated Rating	Hold		High	i
1/31/2020	Morgan Stanley	Boost Price Target	Overweight	$250.00 ➝ $251.00	Low	i Rating by Matthew Harrison at Morgan Stanley
1/31/2020	Stifel Nicolaus	Boost Price Target	Buy	$243.00 ➝ $275.00	High	i
1/31/2020	Royal Bank of Canada	Boost Price Target	Outperform	$240.00 ➝ $260.00	High	i Rating by Brian Abrahams at Royal Bank of Canada
1/31/2020	Cfra	Boost Price Target	Buy	$237.00 ➝ $286.00	High	i
1/31/2020	Credit Suisse Group	Boost Price Target	Outperform	$253.00 ➝ $258.00	High	i Rating by Evan Seigerman at Credit Suisse Group AG
1/31/2020	SunTrust Banks	Reiterated Rating	Buy	$285.00	High	i
1/31/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$247.00 ➝ $260.00	High	i Rating by Cory Kasimov at JPMorgan Chase & Co.
1/31/2020	HC Wainwright	Boost Price Target	Buy	$220.00 ➝ $270.00	High	i
1/31/2020	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$210.00 ➝ $230.00	High	i Rating by Brian Skorney at Robert W. Baird
1/14/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
1/9/2020	BMO Capital Markets	Boost Price Target		$248.00 ➝ $268.00	Low	i Rating by Do Kim at BMO Capital Markets
1/8/2020	Oppenheimer	Boost Price Target	Outperform	$230.00 ➝ $265.00	Low	i
1/6/2020	Piper Jaffray Companies	Boost Price Target	Overweight	$247.00 ➝ $284.00	N/A	i
1/2/2020	Raymond James	Downgrade	Outperform ➝ Market Perform		Low	i
12/18/2019	JPMorgan Chase & Co.	Boost Price Target	Overweight	$218.00 ➝ $247.00	Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
12/16/2019	Argus	Boost Price Target	Buy	$248.00	Medium	i
12/13/2019	Credit Suisse Group	Upgrade	Buy	$231.00	Low	i Rating by Evan Seigerman at Credit Suisse Group AG
11/20/2019	BMO Capital Markets	Boost Price Target	Outperform ➝ Positive	$248.00	Low	i Rating by Do Kim at BMO Capital Markets
11/19/2019	Cowen	Reiterated Rating	Buy		Low	i Rating by Phil Nadeau at Cowen Inc
11/19/2019	Guggenheim	Upgrade	Neutral ➝ Buy	$252.00	High	i
11/12/2019	SunTrust Banks	Initiated Coverage	Buy	$235.00	Medium	i
11/4/2019	Credit Suisse Group	Reiterated Rating	Buy	$228.00	Low	i
11/1/2019	Maxim Group	Reiterated Rating	Hold		High	i
10/31/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$230.00 ➝ $247.00	High	i
10/22/2019	Credit Suisse Group	Boost Price Target	Overweight	$213.00 ➝ $221.00	Low	i
10/22/2019	SVB Leerink	Boost Price Target	Market Perform	$186.00 ➝ $203.00	High	i
10/22/2019	Citigroup	Boost Price Target	Buy	$205.00 ➝ $225.00	High	i
10/21/2019	BMO Capital Markets	Set Price Target	Buy	$232.00	Medium	i Rating by Do Kim at BMO Capital Markets
10/21/2019	Jefferies Financial Group	Set Price Target	Buy	$220.00	Medium	i Rating by Michael Yee at Jefferies Financial Group Inc.
10/21/2019	Cowen	Set Price Target	Buy	$220.00	Medium	i Rating by Phil Nadeau at Cowen Inc
10/21/2019	Robert W. Baird	Set Price Target	Buy	$210.00	Medium	i Rating by Brian Skorney at Robert W. Baird
10/21/2019	JPMorgan Chase & Co.	Set Price Target	Buy	$218.00	Medium	i Rating by Cory Kasimov at JPMorgan Chase & Co.
10/16/2019	Bank of America	Initiated Coverage	Buy	$220.00	Medium	i
9/23/2019	Jefferies Financial Group	Boost Price Target		$210.00 ➝ $220.00	Medium	i
9/6/2019	Morgan Stanley	Boost Price Target	Overweight	$215.00 ➝ $240.00	Low	i
9/3/2019	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$226.00 ➝ $254.00	High	i
8/12/2019	Royal Bank of Canada	Set Price Target	Buy	$213.00	Low	i Rating by Brian Abrahams at Royal Bank of Canada
8/2/2019	Maxim Group	Reiterated Rating	Hold		Low	i
8/1/2019	Credit Suisse Group	Boost Price Target	Outperform	$209.00 ➝ $213.00	Low	i
8/1/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$217.00 ➝ $230.00	Low	i
8/1/2019	Stifel Nicolaus	Boost Price Target	Buy	$205.00 ➝ $211.00	Low	i
8/1/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$212.00	High	i Rating by Cory Kasimov at JPMorgan Chase & Co.
8/1/2019	HC Wainwright	Reiterated Rating	Buy	$220.00	High	i
8/1/2019	Needham & Company LLC	Downgrade	Buy ➝ Hold		High	i
7/31/2019	Cowen	Set Price Target	Buy	$220.00	N/A	i Rating by Phil Nadeau at Cowen Inc
6/2/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low	i
5/23/2019	The Goldman Sachs Group	Reiterated Rating	Buy	$220.00	Low	i
5/23/2019	Citigroup	Reiterated Rating	Buy ➝ Buy	$205.00	Low	i
5/20/2019	Credit Suisse Group	Initiated Coverage	Outperform	$209.00 ➝ $209.00	Medium	i
5/1/2019	Needham & Company LLC	Reiterated Rating	Buy	$195.00	Low	i
5/1/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$209.00	High	i
4/30/2019	Cowen	Reiterated Rating	Buy	$220.00	High	i
4/11/2019	Evercore ISI	Initiated Coverage	In-Line	$183.00	Low	i
3/26/2019	William Blair	Upgrade	Market Perform ➝ Outperform	$183.85	Medium	i Rating by Y. Xu at William Blair
3/19/2019	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$185.40	Medium	i
3/7/2019	Oppenheimer	Boost Price Target	Outperform ➝ Outperform	$200.00 ➝ $230.00	Low	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
3/6/2019	Cowen	Reiterated Rating	Buy	$220.00	Medium	i
3/6/2019	Maxim Group	Reiterated Rating	Hold		Medium	i
2/6/2019	BMO Capital Markets	Boost Price Target	Outperform	$234.00	High	i
2/6/2019	Maxim Group	Downgrade	Buy ➝ Hold		High	i
1/4/2019	Citigroup	Lower Price Target	Buy ➝ Buy	$206.00 ➝ $205.00	Medium	i
1/2/2019	Raymond James	Downgrade	Outperform ➝ Market Perform	$165.71	Low	i Rating by Laura Chico at Raymond James
12/19/2018	Morgan Stanley	Lower Price Target	Overweight ➝ Overweight	$211.00 ➝ $210.00	High	i
12/17/2018	Guggenheim	Initiated Coverage	Neutral		Medium	i Rating by Whitney Ijem at Guggenheim
12/17/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$217.00	High	i
11/27/2018	Oppenheimer	Set Price Target	Buy	$200.00	High	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
11/27/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$217.00	Low	i
10/26/2018	Piper Jaffray Companies	Lower Price Target	Overweight	$217.00	Medium	i
10/26/2018	HC Wainwright	Upgrade	Neutral ➝ Buy	$220.00	High	i
10/25/2018	BMO Capital Markets	Lower Price Target	Outperform	$204.00 ➝ $192.00	High	i
10/25/2018	Raymond James	Set Price Target	Buy	$211.00 ➝ $201.00	High	i Rating by Laura Chico at Raymond James
10/24/2018	JPMorgan Chase & Co.	Reiterated Rating	Buy		Medium	i Rating by Cory Kasimov at JPMorgan Chase & Co.
10/2/2018	Raymond James	Initiated Coverage	Buy		Low	i Rating by Laura Chico at Raymond James
10/1/2018	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$217.00	Medium	i
8/28/2018	Argus	Boost Price Target	Buy ➝ Average	$200.00	High	i Rating by Jasper Hellweg at Argus
8/7/2018	Stifel Nicolaus	Boost Price Target	Buy	$182.00 ➝ $200.00	Medium	i
7/30/2018	Citigroup	Boost Price Target	Buy ➝ Buy	$203.00 ➝ $206.00	Medium	i
7/26/2018	Royal Bank of Canada	Reiterated Rating	Buy	$203.00	Medium	i
7/26/2018	UBS Group	Boost Price Target	Neutral ➝ Neutral	$183.00 ➝ $188.00	High	i
7/26/2018	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$207.00 ➝ $211.00	High	i
7/26/2018	Oppenheimer	Boost Price Target	Outperform	$180.00 ➝ $200.00	High	i
7/26/2018	Piper Jaffray Companies	Boost Price Target	Overweight	$230.00	High	i
7/26/2018	BMO Capital Markets	Boost Price Target	Outperform	$204.00	High	i
7/16/2018	Jefferies Financial Group	Boost Price Target	Buy	$210.00	Low	i
7/1/2018	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
6/12/2018	Argus	Set Price Target	Buy ➝ Buy	$172.00	Low	i Rating by Jasper Hellweg at Argus
4/27/2018	Cowen	Reiterated Rating	Buy	$200.00	Low	i
4/27/2018	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$200.00 ➝ $207.00	Low	i
4/27/2018	Maxim Group	Reiterated Rating	Buy	$200.00	High	i Rating by Jason McCarthy at Maxim Group
3/5/2018	Maxim Group	Boost Price Target	Buy ➝ Buy	$195.00 ➝ $200.00	Medium	i
2/23/2018	Argus	Set Price Target	Buy ➝ Buy	$194.00	High	i
2/13/2018	JMP Securities	Reiterated Rating	Market Outperform ➝ Outperform	$200.00 ➝ $211.00	Low	i
2/13/2018	Credit Suisse Group	Boost Price Target	Outperform ➝ Outperform	$195.00 ➝ $196.00	Low	i
2/13/2018	HC Wainwright	Reiterated Rating	Hold	$103.00	Low	i
2/2/2018	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$198.00 ➝ $200.00	Medium	i
2/1/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$180.00 ➝ $197.00	High	i
2/1/2018	HC Wainwright	Reiterated Rating	Hold	$103.00	High	i
2/1/2018	Citigroup	Reiterated Rating	Buy		High	i
2/1/2018	BMO Capital Markets	Boost Price Target	Outperform ➝ Buy	$184.00 ➝ $191.00	High	i
2/1/2018	SVB Leerink	Reiterated Rating	Outperform	$175.00 ➝ $190.00	High	i
2/1/2018	Royal Bank of Canada	Boost Price Target	Outperform	$200.00	High	i
2/1/2018	Jefferies Financial Group	Reiterated Rating	Buy	$195.00	High	i
2/1/2018	Barclays	Boost Price Target	Overweight ➝ Overweight	$180.00 ➝ $200.00	High	i
1/31/2018	Maxim Group	Reiterated Rating	Buy	$195.00	Low	i
1/23/2018	Bank of America	Reiterated Rating	Buy	$180.00	Low	i
1/9/2018	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
1/5/2018	Bank of America	Upgrade	Neutral ➝ Buy	$180.00	Low	i
1/4/2018	Oppenheimer	Boost Price Target	Outperform	$175.00 ➝ $190.00	Low	i
12/12/2017	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy	$175.00	High	i
12/11/2017	Cowen	Reiterated Rating	Buy	$200.00	Low	i
10/27/2017	Royal Bank of Canada	Reiterated Rating	Buy		N/A	i
10/27/2017	Needham & Company LLC	Reiterated Rating	Buy	$195.00	N/A	i Rating by Danielle Brill at Needham & Company LLC
10/27/2017	Robert W. Baird	Reiterated Rating	Buy		N/A	i
10/26/2017	HC Wainwright	Reiterated Rating	Hold	$85.00	N/A	i
10/26/2017	Maxim Group	Reiterated Rating	Buy	$195.00	N/A	i Rating by Gabrielle Zhou at Maxim Group
10/26/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$205.00	N/A	i
10/18/2017	Royal Bank of Canada	Boost Price Target	Outperform ➝ Outperform	$175.00 ➝ $181.00	N/A	i
9/29/2017	DA Davidson	Initiated Coverage	Buy	$200.00	Low	i
9/29/2017	BTIG Research	Initiated Coverage	Buy ➝ Buy	$200.00	Medium	i
9/27/2017	BMO Capital Markets	Reiterated Rating	Buy		Low	i
9/17/2017	Needham & Company LLC	Reiterated Rating	Buy	$195.00	Low	i Rating by Danielle Brill at Needham & Company LLC
9/14/2017	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Outperform	$175.00	Low	i
8/22/2017	Jefferies Financial Group	Reiterated Rating	Buy		High	i
8/1/2017	Cowen	Reiterated Rating	Buy		Medium	i Rating by Phil Nadeau at Cowen Inc
8/1/2017	Argus	Boost Price Target	Buy	$71.46 ➝ $175.00	Low	i
7/27/2017	BMO Capital Markets	Reiterated Rating	Outperform	$180.00 ➝ $182.00	Low	i
7/27/2017	Oppenheimer	Boost Price Target	Outperform	$150.00 ➝ $175.00	Medium	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
7/27/2017	JPMorgan Chase & Co.	Set Price Target	Buy	$175.00 ➝ $184.00	High	i Rating by Cory Kasimov at JPMorgan Chase & Co.
7/27/2017	Maxim Group	Set Price Target	Buy	$195.00	High	i Rating by Gabrielle Zhou at Maxim Group
7/22/2017	Morgan Stanley	Reiterated Rating	Overweight	$153.00 ➝ $190.00	Low	i
7/21/2017	Robert W. Baird	Reiterated Rating	Outperform	$136.00 ➝ $171.00	Low	i Rating by Brian Skorney at Robert W. Baird
7/21/2017	Needham & Company LLC	Reiterated Rating	Buy	$155.00 ➝ $195.00	Low	i Rating by Danielle Brill at Needham & Company LLC
7/21/2017	BMO Capital Markets	Reiterated Rating	Outperform	$132.00 ➝ $180.00	Low	i
7/21/2017	Citigroup	Reiterated Rating	Buy	$135.00 ➝ $190.00	Low	i
7/19/2017	JPMorgan Chase & Co.	Set Price Target	Buy	$129.00 ➝ $175.00	Low	i Rating by Cory Kasimov at JPMorgan Chase & Co.
7/19/2017	Maxim Group	Set Price Target	Buy	$143.00 ➝ $195.00	Low	i Rating by Jason McCarthy at Maxim Group
7/19/2017	UBS Group	Downgrade	Buy ➝ Neutral	$135.00 ➝ $174.00	High	i
7/19/2017	Credit Suisse Group	Boost Price Target	Outperform	$125.00 ➝ $195.00	High	i
7/19/2017	JMP Securities	Reiterated Rating	Outperform		High	i
7/19/2017	Raymond James	Upgrade	Market Perform ➝ Outperform	$181.00	High	i
7/19/2017	Piper Jaffray Companies	Boost Price Target	Overweight	$194.00	High	i
7/19/2017	Jefferies Financial Group	Reiterated Rating	Buy	$155.00 ➝ $185.00	High	i
7/19/2017	HC Wainwright	Reiterated Rating	Hold	$85.00	High	i Rating by Andrew Fein at HC Wainwright
7/19/2017	Janney Montgomery Scott	Upgrade	Neutral ➝ Buy	$98.00	High	i
7/19/2017	Cowen	Upgrade	Market Perform ➝ Outperform	$105.00 ➝ $200.00	High	i Rating by Phil Nadeau at Cowen Inc
7/19/2017	Barclays	Upgrade	Equal Weight ➝ Overweight	$115.00 ➝ $180.00	High	i
7/18/2017	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$130.00 ➝ $154.00	High	i
7/10/2017	Jefferies Financial Group	Initiated Coverage	Buy ➝ Buy	$155.00	High	i
7/6/2017	Cowen	Reiterated Rating	Market Perform	$105.00	Low	i Rating by Phil Nadeau at Cowen Inc
6/23/2017	Needham & Company LLC	Upgrade	Hold ➝ Buy	$155.00	Medium	i
6/22/2017	SVB Leerink	Reiterated Rating	Outperform		Medium	i
6/9/2017	Jefferies Financial Group	Reiterated Rating	Buy	$126.00	Low	i Rating by Brian Abrahams at Jefferies Financial Group Inc.
6/2/2017	CIBC	Upgrade	Market Perform ➝ Outperform		Low	i
6/2/2017	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$150.00	Medium	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
5/19/2017	Maxim Group	Set Price Target	Buy	$143.00	Low	i Rating by Jason McCarthy at Maxim Group
5/19/2017	UBS Group	Reiterated Rating	Buy	$132.00 ➝ $135.00	N/A	i
5/19/2017	JMP Securities	Reiterated Rating	Outperform	$125.00 ➝ $127.00	Low	i
5/19/2017	Bank of America	Reiterated Rating	Neutral	$121.00 ➝ $125.00	Low	i
5/19/2017	Morgan Stanley	Reiterated Rating	Overweight	$150.00 ➝ $153.00	Low	i
5/2/2017	Jefferies Financial Group	Reiterated Rating	Buy	$126.00	High	i Rating by Brian Abrahams at Jefferies Financial Group Inc.
4/30/2017	Oppenheimer	Reiterated Rating	Hold		Low	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
4/28/2017	Needham & Company LLC	Reiterated Rating	Hold		Low	i
4/28/2017	Robert W. Baird	Boost Price Target	Outperform	$115.00 ➝ $136.00	Low	i Rating by Brian Skorney at Robert W. Baird
4/28/2017	Credit Suisse Group	Boost Price Target	Outperform	$108.00 ➝ $125.00	Low	i Rating by Alethia Young at Credit Suisse Group AG
4/28/2017	Maxim Group	Reiterated Rating	Buy	$143.00	High	i Rating by Jason McCarthy at Maxim Group
4/23/2017	Barclays	Reiterated Rating	Equal Weight	$90.00 ➝ $100.00	Low	i
4/4/2017	Credit Suisse Group	Reiterated Rating	Hold	$108.00	Medium	i Rating by Alethia Young at Credit Suisse Group AG
4/2/2017	HC Wainwright	Reiterated Rating	Neutral	$85.00	Low	i Rating by Andrew Fein at HC Wainwright
3/31/2017	JMP Securities	Reiterated Rating	Outperform	$115.00 ➝ $121.00	Medium	i
3/31/2017	Maxim Group	Upgrade	Hold ➝ Buy	$143.00	Low	i Rating by Jason McCarthy at Maxim Group
3/30/2017	Cowen	Reiterated Rating	Market Perform	$75.00	Low	i Rating by Phil Nadeau at Cowen Inc
3/29/2017	Citigroup	Boost Price Target	Buy	$105.00 ➝ $124.00	Low	i
3/29/2017	Robert W. Baird	Reiterated Rating	Outperform	$115.00	Low	i Rating by Brian Skorney at Robert W. Baird
3/29/2017	Credit Suisse Group	Boost Price Target	Outperform	$100.00 ➝ $108.00	Low	i Rating by Alethia Young at Credit Suisse Group AG
3/29/2017	Stifel Nicolaus	Boost Price Target	Buy	$100.00 ➝ $129.00	High	i Rating by Adam Walsh at Stifel Nicolaus
3/29/2017	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$89.67 ➝ $100.00	High	i
3/29/2017	Jefferies Financial Group	Reiterated Rating	Buy	$100.00	High	i Rating by Brian Abrahams at Jefferies Financial Group Inc.
3/20/2017	SVB Leerink	Reiterated Rating	Outperform		Medium	i
3/17/2017	JMP Securities	Upgrade	Market Perform ➝ Outperform	$103.73 ➝ $115.00	Low	i
3/14/2017	Argus	Reiterated Rating	Buy	$115.00 ➝ $92.95	Low	i
3/9/2017	UBS Group	Initiated Coverage	Buy ➝ Buy	$106.00	N/A	i
3/7/2017	BMO Capital Markets	Reiterated Rating	Market Perform	$78.00	N/A	i
3/6/2017	Robert W. Baird	Reiterated Rating	Outperform	$115.00	N/A	i Rating by Brian Skorney at Robert W. Baird
3/1/2017	Citigroup	Initiated Coverage	Buy ➝ Buy	$105.00	N/A	i
2/27/2017	Oppenheimer	Reiterated Rating	Hold		N/A	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
2/11/2017	Cowen	Set Price Target	Hold	$75.00	N/A	i Rating by Phil Nadeau at Cowen Inc
2/10/2017	Robert W. Baird	Reiterated Rating	Outperform ➝ Positive		N/A	i Rating by Brian Skorney at Robert W. Baird
2/3/2017	Maxim Group	Reiterated Rating	Hold		N/A	i Rating by Jason McCarthy at Maxim Group
1/26/2017	HC Wainwright	Set Price Target	Hold	$85.00	N/A	i Rating by Andrew Fein at HC Wainwright
1/26/2017	Maxim Group	Reiterated Rating	Hold		N/A	i Rating by Jason McCarthy at Maxim Group
1/26/2017	Cowen	Reiterated Rating	Hold	$75.00	N/A	i
1/26/2017	Stifel Nicolaus	Lower Price Target	Buy	$108.00 ➝ $100.00	N/A	i Rating by Adam Walsh at Stifel Nicolaus
1/20/2017	Needham & Company LLC	Reiterated Rating	Hold		N/A	i
1/17/2017	Maxim Group	Reiterated Rating	Hold		N/A	i Rating by Jason McCarthy at Maxim Group
1/9/2017	JMP Securities	Downgrade	Market Perform		N/A	i
1/9/2017	Robert W. Baird	Reiterated Rating	Buy	$115.00	N/A	i Rating by Brian Skorney at Robert W. Baird
1/8/2017	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i Rating by Brian Abrahams at Jefferies Financial Group Inc.
1/3/2017	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i
12/25/2016	Piper Jaffray Companies	Set Price Target	Buy	$129.00	N/A	i Rating by Edward Tenthoff at Piper Jaffray Companies
12/23/2016	JMP Securities	Reiterated Rating	Outperform	$103.00	N/A	i
12/20/2016	Credit Suisse Group	Set Price Target	Buy	$100.00	N/A	i Rating by Alethia Young at Credit Suisse Group AG
12/15/2016	Oppenheimer	Initiated Coverage	Market Perform		N/A	i
12/9/2016	Jefferies Financial Group	Reiterated Rating	Buy	$102.00	N/A	i
12/7/2016	Janney Montgomery Scott	Reiterated Rating	Neutral	$98.00	N/A	i Rating by Debjit Chattopadhyay at Janney Montgomery Scott
11/30/2016	Jefferies Financial Group	Reiterated Rating	Buy	$102.00	N/A	i
11/30/2016	BMO Capital Markets	Reiterated Rating	Market Perform	$88.00	N/A	i
11/29/2016	Robert W. Baird	Reiterated Rating	Outperform	$115.00	N/A	i
11/29/2016	Barclays	Downgrade	Overweight ➝ Equal Weight	$100.00 ➝ $90.00	N/A	i
11/17/2016	Janney Montgomery Scott	Initiated Coverage	Neutral	$98.00	N/A	i
11/1/2016	William Blair	Downgrade	Outperform ➝ Market Perform	$105.00 ➝ $81.00	N/A	i Rating by Y. Xu at William Blair
10/28/2016	Stifel Nicolaus	Reiterated Rating	Buy	$109.00 ➝ $108.00	N/A	i Rating by Adam Walsh at Stifel Nicolaus
10/28/2016	Jefferies Financial Group	Reiterated Rating	Buy	$105.00 ➝ $102.00	N/A	i Rating by Brian Abrahams at Jefferies Financial Group Inc.
10/26/2016	SVB Leerink	Reiterated Rating	Outperform	$112.00 ➝ $111.00	N/A	i Rating by geoff porges at SVB Leerink LLC
10/26/2016	BMO Capital Markets	Reiterated Rating	Market Perform	$87.00 ➝ $88.00	N/A	i
10/24/2016	HC Wainwright	Downgrade	Buy ➝ Neutral	$155.00 ➝ $85.00	N/A	i Rating by Andrew Fein at HC Wainwright
10/21/2016	Jefferies Financial Group	Reiterated Rating	Buy	$105.00	N/A	i Rating by Brian Abrahams at Jefferies Financial Group Inc.
10/12/2016	Royal Bank of Canada	Reiterated Rating	Buy		N/A	i Rating by Michael Yee at Royal Bank of Canada
10/12/2016	Jefferies Financial Group	Reiterated Rating	Buy	$104.00	N/A	i Rating by Brian Abrahams at Jefferies Financial Group Inc.
10/5/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight		N/A	i
10/1/2016	Royal Bank of Canada	Reiterated Rating	Buy		N/A	i Rating by Michael Yee at Royal Bank of Canada
9/30/2016	Jefferies Financial Group	Reiterated Rating	Buy	$107.00 ➝ $104.00	N/A	i Rating by Brian Abrahams at Jefferies Financial Group Inc.
9/30/2016	SVB Leerink	Reiterated Rating	Outperform		N/A	i Rating by geoff porges at SVB Leerink LLC
9/30/2016	Robert W. Baird	Reiterated Rating	Neutral	$128.00 ➝ $115.00	N/A	i Rating by Brian Skorney at Robert W. Baird
9/29/2016	Stifel Nicolaus	Set Price Target	Buy	$109.00	N/A	i Rating by Adam Walsh at Stifel Nicolaus
9/29/2016	Maxim Group	Reiterated Rating	Hold		N/A	i Rating by Jason McCarthy at Maxim Group
9/28/2016	Credit Suisse Group	Set Price Target	Buy	$110.00	N/A	i Rating by Alethia Young at Credit Suisse Group AG
9/17/2016	SVB Leerink	Set Price Target	Buy	$112.00	N/A	i Rating by geoff porges at SVB Leerink LLC
9/15/2016	Jefferies Financial Group	Reiterated Rating	Buy	$107.00	N/A	i Rating by Brian Abrahams at Jefferies Financial Group Inc.
9/15/2016	BMO Capital Markets	Reiterated Rating	Hold	$87.00	N/A	i
9/15/2016	SVB Leerink	Reiterated Rating	Outperform	$113.00	N/A	i Rating by Geoff Porges at SVB Leerink LLC
9/15/2016	Stifel Nicolaus	Boost Price Target	Buy	$105.00 ➝ $109.00	N/A	i
9/13/2016	Citigroup	Initiated Coverage	Market Perform		N/A	i
9/13/2016	Raymond James	Initiated Coverage	Market Perform		N/A	i
8/16/2016	Robert W. Baird	Reiterated Rating	Outperform	$128.00	N/A	i Rating by Brian Skorney at Robert W. Baird
8/16/2016	Jefferies Financial Group	Reiterated Rating	Buy	$107.00	N/A	i Rating by Brian Abrahams at Jefferies Financial Group Inc.
8/16/2016	Royal Bank of Canada	Reiterated Rating	Buy		N/A	i
8/16/2016	JMP Securities	Reiterated Rating	Buy		N/A	i
8/16/2016	Maxim Group	Reiterated Rating	Hold		N/A	i Rating by jason mccarthy at Maxim Group
8/16/2016	Stifel Nicolaus	Lower Price Target	Buy	$108.00 ➝ $105.00	N/A	i
8/15/2016	SVB Leerink	Reiterated Rating	Outperform	$113.00	N/A	i Rating by Geoff Porges at SVB Leerink LLC
7/31/2016	Jefferies Financial Group	Reiterated Rating	Buy	$102.00 ➝ $107.00	N/A	i Rating by Brian Abrahams at Jefferies Financial Group Inc.
7/31/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i Rating by Cory Kasimov at JPMorgan Chase & Co.
7/28/2016	Maxim Group	Reiterated Rating	Hold		N/A	i Rating by Jason McCarthy at Maxim Group
7/28/2016	Cowen	Reiterated Rating	Hold		N/A	i Rating by Phil Nadeau at Cowen Inc
7/28/2016	Morgan Stanley	Lower Price Target	Overweight	$140.00 ➝ $139.00	N/A	i Rating by Matthew Harrison at Morgan Stanley
7/28/2016	SVB Leerink	Reiterated Rating	Outperform	$104.00 ➝ $113.00	N/A	i Rating by Geoff Porges at SVB Leerink LLC
7/7/2016	Maxim Group	Reiterated Rating	Hold		N/A	i Rating by Jason McCarthy at Maxim Group
6/18/2016	Piper Jaffray Companies	Reiterated Rating	Buy		N/A	i Rating by Edward Tenthoff at Piper Jaffray Companies
6/17/2016	Jefferies Financial Group	Reiterated Rating	Buy	$103.00	N/A	i Rating by Brian Abrahams at Jefferies Financial Group Inc.
6/16/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A	i
5/31/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i Rating by Brian Abrahams at Jefferies Financial Group Inc.
5/12/2016	Morgan Stanley	Reiterated Rating	Buy		N/A	i Rating by Matthew Harrison at Morgan Stanley
5/1/2016	Robert W. Baird	Reiterated Rating	Outperform	$144.00 ➝ $128.00	N/A	i Rating by Brian Skorney at Robert W. Baird
4/28/2016	SVB Leerink	Reiterated Rating	Buy		N/A	i Rating by Geoff Porges at SVB Leerink LLC
4/28/2016	Needham & Company LLC	Reiterated Rating	Hold		N/A	i Rating by Alan Carr at Needham & Company LLC
4/28/2016	HC Wainwright	Reiterated Rating	Buy	$155.00	N/A	i Rating by Andrew Fein at HC Wainwright
4/28/2016	Maxim Group	Reiterated Rating	Hold		N/A	i Rating by Jason McCarthy at Maxim Group
4/28/2016	Barclays	Lower Price Target	Overweight	$135.00 ➝ $110.00	N/A	i
4/28/2016	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$109.00 ➝ $88.00	N/A	i
4/28/2016	Royal Bank of Canada	Lower Price Target	Outperform	$135.00 ➝ $115.00	N/A	i Rating by Michael Yee at Royal Bank of Canada
4/25/2016	Robert W. Baird	Reiterated Rating	Buy		N/A	i Rating by Brian Skorney at Robert W. Baird
4/17/2016	Cowen	Reiterated Rating	Hold		N/A	i Rating by Phil Nadeau at Cowen Inc
4/11/2016	Credit Suisse Group	Lower Price Target	Outperform	$143.00 ➝ $112.00	N/A	i
4/10/2016	SVB Leerink	Reiterated Rating	Outperform		N/A	i Rating by Geoff Porges at SVB Leerink LLC
4/7/2016	BMO Capital Markets	Initiated Coverage	Market Perform	$90.00	N/A	i
4/6/2016	Jefferies Financial Group	Lower Price Target	Buy	$108.00	N/A	i Rating by Brian Abrahams at Jefferies Financial Group Inc.
4/4/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy		N/A	i Rating by Cory Kasimov at JPMorgan Chase & Co.
4/1/2016	Stifel Nicolaus	Lower Price Target	Buy	$140.00 ➝ $108.00	N/A	i Rating by Adam Walsh at Stifel Nicolaus
3/28/2016	Guggenheim	Lower Price Target	Buy	$145.00 ➝ $114.00	N/A	i
3/27/2016	Jefferies Financial Group	Reiterated Rating	Buy	$116.00	N/A	i Rating by Brian Abrahams at Jefferies Financial Group Inc.
3/23/2016	Piper Jaffray Companies	Reiterated Rating	Buy		N/A	i Rating by Edward Tenthoff at Piper Jaffray Companies
3/23/2016	The Goldman Sachs Group	Lower Price Target	Buy	$129.00 ➝ $106.00	N/A	i
3/19/2016	Royal Bank of Canada	Reiterated Rating	Buy		N/A	i Rating by Michael Yee at Royal Bank of Canada
3/18/2016	Royal Bank of Canada	Lower Price Target	Outperform	$145.00 ➝ $135.00	N/A	i Rating by Michael Yee at Royal Bank of Canada
3/15/2016	Bank of America	Reiterated Rating	Neutral	$108.00	N/A	i
3/14/2016	SVB Leerink	Reiterated Rating	Outperform	$128.00	N/A	i Rating by Geoff Porges at SVB Leerink LLC
3/11/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$131.00	N/A	i Rating by Edward Tenthoff at Piper Jaffray Companies
3/10/2016	Maxim Group	Reiterated Rating	Hold		N/A	i

(Data available from 3/9/2016 forward)

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $213.58

$211.76

$219.30

50 Day Range

MA: $218.98

$207.02

$241.31

52 Week Range

Now: $213.58

$197.47

$306.08

Volume

3,419,701 shs

Average Volume

2,228,837 shs

Market Capitalization

$55.52 billion

P/E Ratio

26.97

Dividend Yield

N/A

Beta

0.79

Frequently Asked Questions

What sell-side analysts currently cover shares of Vertex Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on Vertex Pharmaceuticals in the last twelve months: Argus, BMO Capital Markets, Cantor Fitzgerald, Cfra, Citigroup Inc., Cowen Inc, Credit Suisse Group AG, Daiwa Capital Markets, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, JPMorgan Chase & Co., Maxim Group, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, Stifel Nicolaus, SunTrust Banks, Inc., SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist, UBS Group AG, and Wolfe Research.
View the latest analyst ratings for VRTX.

What is the current price target for Vertex Pharmaceuticals?

25 Wall Street analysts have set twelve-month price targets for Vertex Pharmaceuticals in the last year. Their average twelve-month price target is $292.68, suggesting a possible upside of 37.0%. Piper Sandler has the highest price target set, predicting VRTX will reach $347.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $250.00 for Vertex Pharmaceuticals in the next year.
View the latest price targets for VRTX.

What is the current consensus analyst rating for Vertex Pharmaceuticals?

Vertex Pharmaceuticals currently has 4 hold ratings, 22 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VRTX will outperform the market and that investors should add to their positions of Vertex Pharmaceuticals.
View the latest ratings for VRTX.

What other companies compete with Vertex Pharmaceuticals?

Other companies that are similar to Vertex Pharmaceuticals include Amgen, Gilead Sciences, Regeneron Pharmaceuticals, Biogen, Alexion Pharmaceuticals, Seagen, Exact Sciences, Incyte, Alnylam Pharmaceuticals, BioMarin Pharmaceutical, Novavax, Repligen, Neurocrine Biosciences, Ionis Pharmaceuticals and United Therapeutics.

How do I contact Vertex Pharmaceuticals' investor relations team?

Vertex Pharmaceuticals' physical mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company's listed phone number is 617-341-6100 and its investor relations email address is [email protected] The official website for Vertex Pharmaceuticals is www.vrtx.com.

NASDAQ:VRTX - Vertex Pharmaceuticals Stock Price Target and Predictions

Analyst Price Target for VRTX

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Vertex Pharmaceuticals?

What is the current price target for Vertex Pharmaceuticals?

What is the current consensus analyst rating for Vertex Pharmaceuticals?

What other companies compete with Vertex Pharmaceuticals?

How do I contact Vertex Pharmaceuticals' investor relations team?